Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Stoke Therapeutics stock

STOK
US86150R1077
A2PLTL

Price

7.85
Today +/-
-0.13
Today %
-1.77 %

Stoke Therapeutics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Stoke Therapeutics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Stoke Therapeutics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Stoke Therapeutics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Stoke Therapeutics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Stoke Therapeutics Stock Price History

DateStoke Therapeutics Price
2/27/20257.85 undefined
2/26/20257.99 undefined
2/25/20258.27 undefined
2/24/20258.25 undefined
2/23/20258.50 undefined
2/20/20258.33 undefined
2/19/20258.74 undefined
2/18/20259.30 undefined
2/17/20259.71 undefined
2/13/202510.68 undefined
2/12/202510.63 undefined
2/11/202510.26 undefined
2/10/202510.32 undefined
2/9/202510.27 undefined
2/6/202511.35 undefined
2/5/202512.74 undefined
2/4/202512.70 undefined
2/3/202512.60 undefined
2/2/202511.52 undefined

Stoke Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Stoke Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Stoke Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Stoke Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Stoke Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Stoke Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Stoke Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Stoke Therapeutics’s growth potential.

Stoke Therapeutics Revenue, EBIT and net profit per share

DateStoke Therapeutics RevenueStoke Therapeutics EBITStoke Therapeutics Net Income
2030e548.4 M undefined0 undefined217.74 M undefined
2029e292.91 M undefined75.73 M undefined102.39 M undefined
2028e110.79 M undefined-121.89 M undefined-78.99 M undefined
2027e60.5 M undefined-117.8 M undefined-88.61 M undefined
2026e24.91 M undefined-184.13 M undefined-144.06 M undefined
2025e20.77 M undefined-152.75 M undefined-114.73 M undefined
2024e18.04 M undefined-122.73 M undefined-109.03 M undefined
20238.78 M undefined-114.77 M undefined-104.7 M undefined
202212.41 M undefined-104.36 M undefined-101.07 M undefined
20210 undefined-86.07 M undefined-85.81 M undefined
20200 undefined-53.04 M undefined-52.24 M undefined
20190 undefined-35.68 M undefined-32.33 M undefined
20180 undefined-12.78 M undefined-12.52 M undefined
20170 undefined-5.55 M undefined-5.56 M undefined

Stoke Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20172018201920202021202220232024e2025e2026e2027e2028e2029e2030e
0000012818202460110292548
-------33.33125.0011.1120.00150.0083.33165.4587.67
--------------
00000000000000
-5-12-32-52-85-101-104-109-114-144-88-78102217
-140.00166.6762.5063.4618.822.974.814.5926.32-38.89-11.36-230.77112.75
30.2730.2730.2733.4936.7438.943.990000000
--------------
Details

Keystats

ⓘ

Revenue and Growth

The Stoke Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Stoke Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (k)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (k)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
2017201820192020202120222023
             
1.8105.4222.5287.3219.8229.6201.39
0000000
0000000
0000000
0.10.53.36.69.313.913.88
1.9105.9225.8293.9229.1243.5215.28
0.51.22.53.89.111.412.43
0000000
0000000
0000000
0000000
100200200200600600569
0.61.42.749.71213
2.5107.3228.5297.9238.8255.5228.28
             
0000005
11.9130.8282.5396.4414483.2561.43
-13.2-25.7-58-110.3-196.1-297.2-401.85
0000-0.2-1.2-0.02
0000000
-1.3105.1224.5286.1217.7184.8159.57
0.11.10.81.52.40.81.7
0.61.43.38.514.215.212.96
300.11.40.515.416.17
0000000
0000000
3.72.54.211.417.131.430.82
0000000
0000000
000.20.43.939.837.96
000.20.43.939.837.96
3.72.54.411.82171.268.78
2.4107.6228.9297.9238.7256228.34
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Stoke Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Stoke Therapeutics's financial health and stability.

Assets

Stoke Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Stoke Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Stoke Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Stoke Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2017201820192020202120222023
-5-12-32-52-85-101-104
0000012
0000000
01-12043-6
00312344752
0000000
0000000
-5-10-31-42-66-31-81
00-1-1-1-3-1
00-1-1-76-45105
0000-75-41107
0000000
0000000
6116152108110
511514910814653
00-2004552
0000000
010311764-142-3177
-5.49-11.9-32.7-43.27-68.11-35.83-82.68
0000000

Stoke Therapeutics stock margins

The Stoke Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Stoke Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Stoke Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Stoke Therapeutics's sales revenue. A higher gross margin percentage indicates that the Stoke Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Stoke Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Stoke Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Stoke Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Stoke Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Stoke Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Stoke Therapeutics Margin History

Stoke Therapeutics Gross marginStoke Therapeutics Profit marginStoke Therapeutics EBIT marginStoke Therapeutics Profit margin
2030e0 %0 %39.7 %
2029e0 %25.85 %34.95 %
2028e0 %-110.02 %-71.3 %
2027e0 %-194.71 %-146.46 %
2026e0 %-739.22 %-578.33 %
2025e0 %-735.63 %-552.52 %
2024e0 %-680.47 %-604.52 %
20230 %-1,307.21 %-1,192.47 %
20220 %-840.93 %-814.42 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %

Stoke Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The Stoke Therapeutics earnings per share therefore indicates how much revenue Stoke Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Stoke Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Stoke Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Stoke Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Stoke Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Stoke Therapeutics Revenue, EBIT and net profit per share

DateStoke Therapeutics Sales per ShareStoke Therapeutics EBIT per shareStoke Therapeutics Earnings per Share
2030e10.35 undefined0 undefined4.11 undefined
2029e5.53 undefined0 undefined1.93 undefined
2028e2.09 undefined0 undefined-1.49 undefined
2027e1.14 undefined0 undefined-1.67 undefined
2026e0.47 undefined0 undefined-2.72 undefined
2025e0.39 undefined0 undefined-2.17 undefined
2024e0.34 undefined0 undefined-2.06 undefined
20230.2 undefined-2.61 undefined-2.38 undefined
20220.32 undefined-2.68 undefined-2.6 undefined
20210 undefined-2.34 undefined-2.34 undefined
20200 undefined-1.58 undefined-1.56 undefined
20190 undefined-1.18 undefined-1.07 undefined
20180 undefined-0.42 undefined-0.41 undefined
20170 undefined-0.18 undefined-0.18 undefined

Stoke Therapeutics business model

Stoke Therapeutics Inc is a biopharmaceutical company founded in 2018 by experienced scientists to develop innovative therapeutic approaches for rare genetic diseases. The company's headquarters is located in Bedford, Massachusetts, and since its inception, it has continuously invested to expand its business and its development process. In 2019, the company announced a financing round of $90 million to advance the development of its pipeline and clinical trials. Stoke Therapeutics specializes in the development of therapeutics for the treatment of rare genetic diseases caused by mutations in haploinsufficiency genes. These diseases are caused by mutations in one of the two genes that code for a specific protein. Since a single defective gene is not sufficient to maintain the normal functions of a protein, serious health problems arise. Stoke's therapeutics aim to replace the missing gene product by targeted stimulation of the healthy gene. This is achieved through the development of antisense oligonucleotide-based therapeutics. Antisense oligonucleotides are small DNA-like molecules that are able to address, recognize, and bind to specific genes. By binding to the healthy gene, they can promote its expression and thereby replace the missing protein. The company's pipeline currently includes a range of products at various stages of development, including preclinical and clinical trials. The following products are the most important: STK-001: A product developed for the treatment of severe forms of Dravet syndrome. Dravet syndrome is a rare genetic disease characterized by seizures, developmental delays, and other neurological symptoms. STK-002: A product for the treatment of haploinsufficiency in STING1-associated vasculopathic syndrome (SAVS). SAVS is a rare genetic disease characterized by cardiovascular disorders and increased susceptibility to infections. STK-005: A product for the treatment of haploinsufficiency in adrenoleukodystrophy (ALD). ALD is a rare disease characterized by inflammatory and degenerative changes in the nervous system. Due to its innovative technology and focus on rare genetic diseases, Stoke Therapeutics has attracted the attention of many investors and potential partners. In 2020, the company entered into collaboration agreements with Roche Holdings and Ribometrix Inc to accelerate the development and commercialization of its therapeutics. Overall, Stoke Therapeutics has a promising future as it is able to provide a much-needed treatment option for patients with rare genetic diseases who currently have no effective therapies available. Stoke Therapeutics is one of the most popular companies on Eulerpool.com.

Stoke Therapeutics SWOT Analysis

Strengths

Stoke Therapeutics Inc has several key strengths that contribute to its competitive advantage:

  • Strong intellectual property portfolio, providing market exclusivity and protection for its novel therapies.
  • Expertise in RNA-targeted medicines, enabling the development of innovative treatments for genetic diseases.
  • Experienced leadership team with a successful track record in the biotechnology industry.
  • Strategic partnerships with leading research institutions and pharmaceutical companies, facilitating collaborations and access to resources.
  • Robust pipeline of novel therapies addressing high-unmet medical needs in the genetic disease space.

Weaknesses

Stoke Therapeutics Inc faces certain weaknesses that may hinder its growth and success:

  • Reliance on a limited number of product candidates, which increases the risk associated with clinical trials and regulatory approval.
  • Dependency on external funding sources to support research and development activities.
  • Limited market presence and brand recognition compared to established competitors in the biotechnology industry.
  • Market volatility and regulatory challenges affecting the biopharmaceutical sector.

Opportunities

Stoke Therapeutics Inc can leverage the following opportunities to drive growth and expand its market share:

  • Increasing demand for innovative treatments targeting genetic diseases, driven by advancements in genetic research and personalized medicine.
  • Expanding partnerships to access additional resources, expertise, and financial support for research and development initiatives.
  • Emerging markets with unmet medical needs present opportunities for geographical expansion.
  • Advancements in technology, such as gene editing tools, offer new possibilities for developing more precise and effective therapies.

Threats

Stoke Therapeutics Inc must navigate the following threats that could impact its business operations:

  • Competition from well-established pharmaceutical companies with significant resources and market presence.
  • Regulatory hurdles and potential delays in clinical trials and approval processes.
  • Rapidly evolving industry landscape and scientific advancements, requiring continuous innovation to stay ahead.
  • Economic recessions or market downturns affecting funding availability and investor sentiment in the biotechnology sector.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Stoke Therapeutics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Stoke Therapeutics historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Stoke Therapeutics shares outstanding

The number of shares was Stoke Therapeutics in 2024 — This indicates how many shares 43.995 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Stoke Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Stoke Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Stoke Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Stoke Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Stoke Therapeutics.

Stoke Therapeutics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2024-0.54 -0.47  (13.51 %)2024 Q3
6/30/2024-0.57 -0.46  (19.47 %)2024 Q2
3/31/2024-0.62 -0.57  (8.39 %)2024 Q1
12/31/2023-0.64 -0.6  (6.63 %)2023 Q4
9/30/2023-0.65 -0.55  (14.14 %)2023 Q3
6/30/2023-0.65 -0.69  (-6.3 %)2023 Q2
3/31/2023-0.71 -0.53  (25.37 %)2023 Q1
12/31/2022-0.72 -0.65  (9.22 %)2022 Q4
9/30/2022-0.7 -0.66  (5.4 %)2022 Q3
6/30/2022-0.7 -0.63  (10.19 %)2022 Q2
1
2
3

Eulerpool ESG Scorecard© for the Stoke Therapeutics stock

Eulerpool World ESG Rating (EESG©)

59/ 100

🌱 Environment

61

👫 Social

86

🏛️ Governance

31

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees55
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Stoke Therapeutics shareholders

%
Name
Stocks
Change
Date
13.03791 % Skorpios Trust6,906,181-2,000,00012/31/2024
9.79270 % Lynx1 Capital Advisors LLC5,187,191012/31/2024
9.67250 % RTW Investments L.P.5,123,525471,24012/31/2024
8.74804 % Baker Bros. Advisors LP4,633,838265,39512/31/2024
8.67213 % Redmile Group, LLC4,593,629-119,88012/31/2024
5.99067 % TD Securities, Inc.3,173,2583,173,25812/31/2024
5.59165 % Morgan Stanley & Co. LLC2,961,896-551,35912/31/2024
5.34054 % BlackRock Institutional Trust Company, N.A.2,828,882288,00912/31/2024
5.14263 % The Vanguard Group, Inc.2,724,051-28,04912/31/2024
3.77572 % Invus Public Equities Advisors, LLC2,000,0002,000,00012/31/2024
1
2
3
4
5
...
10

Stoke Therapeutics Executives and Management Board

Dr. Edward Kaye

(74)
Stoke Therapeutics Chief Executive Officer, Director (since 2017)
Compensation 5.75 M

Dr. Barry Ticho

(63)
Stoke Therapeutics Chief Medical Officer
Compensation 2.39 M

Mr. Stephen Tulipano

(63)
Stoke Therapeutics Chief Financial Officer
Compensation 2.32 M

Dr. Huw Nash

(56)
Stoke Therapeutics Chief Operating Officer, Chief Business Officer
Compensation 869,855

Dr. Seth Harrison

(62)
Stoke Therapeutics Independent Chairman of the Board
Compensation 252,140
1
2
3

Most common questions regarding Stoke Therapeutics

What values and corporate philosophy does Stoke Therapeutics represent?

Stoke Therapeutics Inc represents values of innovation, collaboration, and commitment to patients. The company's corporate philosophy revolves around developing transformative treatments for severe genetic diseases. Stoke is dedicated to harnessing the power of RNA biology to address the underlying cause of such diseases. By prioritizing scientific advancement and partnerships, Stoke Therapeutics Inc aims to make a positive impact on patients' lives. The company strives to excel in translating cutting-edge research into therapeutic breakthroughs, offering hope and delivering long-term value for patients, their families, and the healthcare community.

In which countries and regions is Stoke Therapeutics primarily present?

Stoke Therapeutics Inc is primarily present in the United States.

What significant milestones has the company Stoke Therapeutics achieved?

Stoke Therapeutics Inc has achieved several significant milestones. The company successfully completed its initial public offering in June 2019, raising approximately $142 million in net proceeds. In January 2020, Stoke Therapeutics received the FDA's rare pediatric disease designation for its lead product candidate, STK-001, which aims to treat Dravet syndrome, a severe form of epilepsy. Furthermore, the company initiated a Phase 1/2a clinical trial of STK-001 in October 2020. Stoke Therapeutics continues to make progress in advancing its pipeline and developing innovative therapies for genetic diseases.

What is the history and background of the company Stoke Therapeutics?

Stoke Therapeutics Inc is a biotechnology company founded in 2018, based in Bedford, Massachusetts. Focused on addressing the underlying causes of severe genetic diseases, Stoke Therapeutics utilizes its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) platform. This platform enables the development of antisense oligonucleotide (ASO) therapies to increase protein levels and restore gene expression. By targeting RNA instead of DNA, Stoke Therapeutics aims to treat a range of genetic disorders, including genetic epilepsies, genetic conditions affecting the central nervous system, and other rare diseases. Their innovative approach holds promise for patients with limited treatment options, making Stoke Therapeutics a key player in the biotech industry.

Who are the main competitors of Stoke Therapeutics in the market?

The main competitors of Stoke Therapeutics Inc in the market include companies such as Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Akcea Therapeutics.

In which industries is Stoke Therapeutics primarily active?

Stoke Therapeutics Inc is primarily active in the biotechnology industry.

What is the business model of Stoke Therapeutics?

The business model of Stoke Therapeutics Inc revolves around developing innovative RNA-targeted therapeutics to treat severe genetic diseases. By focusing on addressing the underlying causes of diseases, Stoke Therapeutics aims to provide long-term solutions for patients. Its proprietary technology platform, Targeted Augmentation of Nuclear Gene Output (TANGO), enables the modulation of gene expression levels to restore the production of functional proteins. Stoke Therapeutics collaborates with industry partners and utilizes its expertise in RNA biology to advance potential therapies for a range of genetic disorders. Through its business model, the company aims to improve the lives of patients with severe genetic diseases through innovative and targeted treatments.

What is the P/E ratio of Stoke Therapeutics 2025?

The Stoke Therapeutics P/E ratio is -3.01.

What is the P/S ratio of Stoke Therapeutics 2025?

The Stoke Therapeutics P/S ratio is 16.63.

What is the Quality Investing of Stoke Therapeutics?

The Quality Investing for Stoke Therapeutics is 3/10.

What is the revenue of Stoke Therapeutics 2025?

The expected Stoke Therapeutics revenue is 20.77 M USD.

How high is the profit of Stoke Therapeutics 2025?

The expected Stoke Therapeutics profit is -114.73 M USD.

What is the business model of Stoke Therapeutics

Stoke Therapeutics Inc. is a biopharmaceutical company focused on developing technologies and therapies for the treatment of rare genetic diseases. Their business model is based on the application of a novel technology platform called Targeted Augmentation of Nuclear Gene Output (TANGO), which allows for the increase or decrease of gene expression. They aim to achieve therapeutic effects by specifically augmenting gene expression through their TANGO platform, which involves developing RNA molecules known as antisense oligonucleotides (ASOs) to modulate gene expression. Stoke Therapeutics has multiple products in various stages of development, with their most advanced candidate, STK-001, targeting the treatment of autosomal recessive spinobulbar muscular atrophy (SMA). They are also working on therapies for other rare diseases such as autosomal dominant optic atrophy (ADOA) and Dravet syndrome. Overall, Stoke Therapeutics focuses on developing RNA-based therapeutics for rare genetic diseases caused by loss-of-function mutations.

What is the Stoke Therapeutics dividend?

Stoke Therapeutics pays a dividend of 0 USD distributed over payouts per year.

How often does Stoke Therapeutics pay dividends?

The dividend cannot currently be calculated for Stoke Therapeutics or the company does not pay out a dividend.

What is the Stoke Therapeutics ISIN?

The ISIN of Stoke Therapeutics is US86150R1077.

What is the Stoke Therapeutics WKN?

The WKN of Stoke Therapeutics is A2PLTL.

What is the Stoke Therapeutics ticker?

The ticker of Stoke Therapeutics is STOK.

How much dividend does Stoke Therapeutics pay?

Over the past 12 months, Stoke Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Stoke Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Stoke Therapeutics?

The current dividend yield of Stoke Therapeutics is .

When does Stoke Therapeutics pay dividends?

Stoke Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Stoke Therapeutics?

Stoke Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Stoke Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Stoke Therapeutics located?

Stoke Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Stoke Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Stoke Therapeutics from 3/3/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 3/3/2025.

When did Stoke Therapeutics pay the last dividend?

The last dividend was paid out on 3/3/2025.

What was the dividend of Stoke Therapeutics in the year 2024?

In the year 2024, Stoke Therapeutics distributed 0 USD as dividends.

In which currency does Stoke Therapeutics pay out the dividend?

The dividends of Stoke Therapeutics are distributed in USD.

All fundamentals about Stoke Therapeutics

Our stock analysis for Stoke Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Stoke Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.